Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cardlytics, Inc. Director's Dealing 2020

Jan 18, 2020

33956_dirs_2020-01-17_09129dc6-6dd5-45c8-bec4-6ef8897e549d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cardlytics, Inc. (CDLX)
CIK: 0001666071
Period of Report: 2020-01-17

Reporting Person: SOMERS KIRK (Chief Legal & Privacy Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-01-17 Common Stock M 778 $20 Acquired 83671 Direct
2020-01-17 Common Stock S 5409 $83.06 Disposed 78262 Direct
2020-01-17 Common Stock S 450 $84.13 Disposed 77812 Direct
2020-01-17 Common Stock S 919 $84.88 Disposed 76893 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-01-17 Employee Stock Option (Right to Buy) $20.0 M 778 Disposed 2026-08-02 Common Stock (778.0) Direct

Footnotes

F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2019.

F2: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $82.83 to $83.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.

F3: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $83.86 to $84.21, inclusive.

F4: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $84.86 to $84.99, inclusive.

F5: This option became exercisable with respect to one quarter (1/4) of the shares of stock subject to this option on June 15, 2017 (the "Initial Vesting Date"). The option becomes exercisable in respect of the remaining shares in thirty-six (36) equal monthly installments commencing one (1) month after the Initial Vesting Date, provided the Reporting Person continuously provides service to the Issuer through each vesting period.